Paul Baas, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, provides an overview of current developments in the mesothelioma treatment landscape. Prof. Baas highlights the potential of chemotherapy and immunotherapy combinations, especially with the approval of nivolumab, atezolizumab, and pembrolizumab. Numerous therapies such as pembrolizumab and lenvatinib are additionally being investigated as second-line treatments, especially in patients pre-treated with immunotherapy. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.